Ependymoma pathophysiology

Jump to navigation Jump to search

Ependymoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Epidemiology and Demographics

Risk Factors

Differentiating Ependymoma from other Diseases

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Staging

Laboratory Findings

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Ependymoma pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Ependymoma pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Ependymoma pathophysiology

CDC on Ependymoma pathophysiology

Ependymoma pathophysiology in the news

Blogs on Ependymoma pathophysiology

Directions to Hospitals Treating Ependymoma

Risk calculators and risk factors for Ependymoma pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2]

Overview

Pathology

  • Ependymomas represent a relatively broad group of glial tumours which share common origin from differentiated ependymal cells lining the ventricles of the brain or the central canal of the spinal cord. They account for ~5% of all neuroepithelial neoplasms, ~10% of all paediatric brain tumours and up to 33% of brain tumours occurring in those less than 3 years of age.
  • Ependymomas can occur anywhere, but certain location are typical. Common locations include:
  • The subependymomas, variant of the ependymoma, arise in the fourth ventricle but may occur in the septum pellucidum and the cervical spinal cord.

Gross Pathology

  • Ependymomas are well-encapsulated tumors and usually arise from the floor of the fourth ventricle, situated in the lower back portion of the brain.

Microscopic Pathology

  • Ependymomas are composed of cells with regular, round to oval nuclei. There is a variably dense fibrillary background.
  • Tumor cells may form gland-like round or elongated structures that resemble the embryologic ependymal canal, with long, delicate processes extending into the lumen; more frequently present are perivascular pseudorosettes in which tumor cells are arranged around vessels with an intervening zone consisting of thin ependymal processes directed toward the wall of the vessel.[2].
  • Ependymal rosettes are rare but pathognomonic feature.

Associated Conditions

The subependymal giant-cell astrocytoma, also called giant-cell glioma, is typically associated with tuberous sclerosis but can occur independently.

Genetics

  • One expression-defined group occurs primarily in young children and is characterized by a largely balanced genomic profile with an increased occurrence of chromosome 1q and proteins such as tenascin C and epidermal growth factor receptor.[8][9]
  • The second expression-defined group occurs primarily in older children and adults and is characterized by a numerous cytogenetic abnormalities involving the whole chromosome or chromosomal arms.[5]
  • Genes involved in ependymoma formation and progression are:[3]
  • ERBB2
  • ERBB4
  • Human telomerase reverse transcriptase TERT
  • KIT receptor tyrosine kinase and phospho-KIT receptor expression is associated with tumor progression
  • MMP2 and MMP14 appear to also play a role in tumor growth and progression in intracranial cases.
  • NOTCH1 mutations have been found in approximately 8% of pediatric ependymomas
  • MEN1 mutations are occasionally found in pediatric ependymomas.
  • TPR and CHIBBY, have been identified in pediatric ependymomas.
  • S100A6 and S100A4 on chromosome 1q have also been found to correspond to supratentorial tumor development and tumors occurring before the age of 3 years old.

References

  1. EPENDYMOMA. http://librepathology.org/wiki/index.php/File:AFIP405713G-EPENDYMOMA.jpg 2015. URL Accessed on 10 6, 2015
  2. Kumar, et al. (2005). The Central Nervous System. Pathologic Basis of Disease. 7th Edition. Philadelphia: Elsevier Saunders.
  3. 3.0 3.1 Ependymoma. https://en.wikipedia.org/wiki/Ependymoma#/media/File:Ependymoma_low_intermed_mag.jpg. URL Accessed on 10 6, 2015
  4. Image courtesy of Dr Dharam RamnaniRadiopaedia (original file‘’here’’).[http://radiopaedia.org/licence CreativeCommons BY-SANC
  5. 5.0 5.1 Koval TM, Myser WC, Hink WF (1975). "Effects of x-irradiation on cell division, oxygen consumption, and growth medium pH of an insect cell line cultured in vitro". Radiat Res. 64 (3): 524–32. PMID 727-38 Check |pmid= value (help).
  6. Sloane NH (1975). "alpha-Naphthoflavone activation of 6-hydroxymethylbenzo(alpha)pyrene synthetase". Cancer Res. 35 (12): 3731–4. PMID 143-57 Check |pmid= value (help).
  7. Eoendymoma. http://www.cancer.gov/types/brain/hp/child-ependymoma-treatment-pdq#section/_35 URL Accessed on 10 6 2015.
  8. Scheyer M, Iannascoli F, Brioude R, Canet J (1975). "[Transport of "high-risk" newborn infants. (Apropos of 159 emergency calls by the SAMU 94-Service d'Aide Médicale Urgente-Emergency Health Service)]". Ann Anesthesiol Fr. 16 Spec No 1: 130–4. PMID 2070-9 Check |pmid= value (help).
  9. Elgart ES, Gusovsky T, Rosenberg MD (1975). "Preparation and characterization of an enzymatically active immobilized derivative of myosin". Biochim Biophys Acta. 410 (1): 178–92. PMID 72-82 Check |pmid= value (help).

Template:WikiDoc Sources